Xiangling Feng, Jiahao Zhou, Zhen He, Xiaomin Ying, Tongtong Kan
{"title":"Shared Genetic Architecture of Epilepsy and Glioma Revealed by Mendelian Randomization: Identifying Prognostic Biomarkers and Therapeutic Targets.","authors":"Xiangling Feng, Jiahao Zhou, Zhen He, Xiaomin Ying, Tongtong Kan","doi":"10.2174/0115680096474313260623050646","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Glioma-Related Epilepsy (GRE) is a hallmark comorbidity of Low-Grade Glioma (LGG), yet the cellular and molecular mechanisms through which germline epilepsy susceptibility converges with tumor biology to shape clinical outcomes remain poorly understood.</p><p><strong>Methods: </strong>Genome-Wide Association Studies (GWAS), expression quantitative trait loci (eQTL) data, single-cell RNA sequencing, and spatial transcriptomics were integrated. Causal inference, phenotype-driven single-cell analyses, and machine learning were applied to identify genetically informed cellular mechanisms underlying GRE.</p><p><strong>Results: </strong>A total of 68 germline loci shared by glioma and epilepsy (FDRIVW < 0.05) were integrated, with microglia and excitatory neurons as the principal mediating cell types. Four seizure-associated genes (WFIKKN1, WDSUB1, SPARCL1, and CALD1) were subsequently identified in TCGA-LGG, with high-confidence enhancer-promoter support for three of them (colco.PP4 > 0.9). A four-gene signature consistently stratified overall survival across three independent cohorts (TCGA-LGG, CGGA_325, and GSE16011) and correlated with immune checkpoint gene expression. High-risk patients showed higher sensitivity to cyclopamine, according to in silico drug response.</p><p><strong>Discussion: </strong>These findings support a neuroimmune model in which pleiotropic germline variants act via microglia and excitatory neurons to link seizure biology with tumor immunity and prognosis. At the same time, in silico therapeutic predictions require functional and multi-ancestry validation.</p><p><strong>Conclusion: </strong>These results reveal a common genetic architecture between glioma and epilepsy, offering candidate biomarkers and therapeutic strategies for the management of GRE.</p>","PeriodicalId":10816,"journal":{"name":"Current cancer drug targets","volume":" ","pages":""},"PeriodicalIF":2.5000,"publicationDate":"2026-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current cancer drug targets","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0115680096474313260623050646","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Glioma-Related Epilepsy (GRE) is a hallmark comorbidity of Low-Grade Glioma (LGG), yet the cellular and molecular mechanisms through which germline epilepsy susceptibility converges with tumor biology to shape clinical outcomes remain poorly understood.
Methods: Genome-Wide Association Studies (GWAS), expression quantitative trait loci (eQTL) data, single-cell RNA sequencing, and spatial transcriptomics were integrated. Causal inference, phenotype-driven single-cell analyses, and machine learning were applied to identify genetically informed cellular mechanisms underlying GRE.
Results: A total of 68 germline loci shared by glioma and epilepsy (FDRIVW < 0.05) were integrated, with microglia and excitatory neurons as the principal mediating cell types. Four seizure-associated genes (WFIKKN1, WDSUB1, SPARCL1, and CALD1) were subsequently identified in TCGA-LGG, with high-confidence enhancer-promoter support for three of them (colco.PP4 > 0.9). A four-gene signature consistently stratified overall survival across three independent cohorts (TCGA-LGG, CGGA_325, and GSE16011) and correlated with immune checkpoint gene expression. High-risk patients showed higher sensitivity to cyclopamine, according to in silico drug response.
Discussion: These findings support a neuroimmune model in which pleiotropic germline variants act via microglia and excitatory neurons to link seizure biology with tumor immunity and prognosis. At the same time, in silico therapeutic predictions require functional and multi-ancestry validation.
Conclusion: These results reveal a common genetic architecture between glioma and epilepsy, offering candidate biomarkers and therapeutic strategies for the management of GRE.
期刊介绍：
Current Cancer Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular drug targets involved in cancer, e.g. disease specific proteins, receptors, enzymes and genes.
Current Cancer Drug Targets publishes original research articles, letters, reviews / mini-reviews, drug clinical trial studies and guest edited thematic issues written by leaders in the field covering a range of current topics on drug targets involved in cancer.
As the discovery, identification, characterization and validation of novel human drug targets for anti-cancer drug discovery continues to grow; this journal has become essential reading for all pharmaceutical scientists involved in drug discovery and development.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
